PHC Holdings Corporation FY2027 Q1 Earnings Report

Quick View

Executive Summary

The key feature of the quarter was a substantial recovery in both revenue and earnings, with Operating Income and Net Income rebounding sharply from the previous year's slump. Revenue was ¥90.67B (¥83.86B in the previous year, +8.1% YoY), while Operating Income was ¥10.41B (¥3.84B in the previous year, +171.0%). Under IFRS, Profit Before Tax was ¥8.13B (¥-1.99B in the previous year), and consolidated Net Income turned profitable at ¥6.29B (¥-2.47B in the previous year). Net Income attributable to owners of the parent was ¥6.34B (¥-2.34B in the previous year). The primary drivers of the earnings growth were strong growth and improved profitability in the core Diabetes Management Business, as well as lower finance costs.

Factors Affecting Performance

【Revenue】Revenue increased 8.1% YoY to ¥90.67B. By segment, Diabetes Management generated ¥27.81B (30.7% of total, +20.2%), Healthcare Solutions generated ¥30.98B (34.2%, +1.6%), and Diagnostics & Life Sciences generated ¥31.80B (35.1%, +5.4%), with Diabetes Management driving company-wide growth.

【Profit and Loss】Operating Income increased 171.0% YoY to ¥10.41B, and the Operating Margin expanded to 11.5% from 4.6% in the previous year, an increase of +690bp. The Gross Margin improved to 48.3% (46.3% in the previous year, +200bp), while the SG&A Expense Ratio declined to 37.5% (41.7% in the previous year, -420bp). The expansion in profitability reflected both improved earnings quality and enhanced cost efficiency. Below Operating Income, finance costs declined substantially to ¥2.40B from ¥5.88B in the previous year, supporting Profit Before Tax of ¥8.13B (¥-1.99B in the previous year). The company is in a phase of growth in both revenue and earnings.

Segment Analysis

By segment, Diabetes Management was the standout earnings source, with Revenue of ¥27.81B (+20.2%), Operating Income of ¥9.18B (+132.2%), and a 33.0% Operating Margin. Healthcare Solutions posted Revenue of ¥30.98B (+1.6%), Operating Income of ¥1.10B (+27.6%), and a 3.5% Operating Margin, while Diagnostics & Life Sciences reported Revenue of ¥31.80B (+5.4%), Operating Income of ¥1.81B (+108.2%), and a 5.7% Operating Margin. Although both segments achieved earnings growth, their margins remained in the single digits. Diabetes Management accounted for 75.9% of the total segment Operating Income of ¥12.09B, indicating a high degree of dependence on this business for company-wide earnings. The company-wide Operating Margin of 11.5% can be interpreted as the result of a business mix reflecting the profitability gap among segments.

Key Financial Indicators

【Profitability】The Operating Margin improved to 11.5% from 4.6% in the previous year, an increase of +690bp, while the Net Profit Margin, based on consolidated Net Income, recovered substantially to 6.9% from -2.9% in the previous year.【Cash Flow Quality】Operating Cash Flow (OCF) of ¥14.33B was 2.3 times consolidated Net Income of ¥6.29B, indicating a favorable level of cash backing for earnings.【Investment Efficiency】ROE was 3.7% (based on Net Income attributable to owners of the parent, quarterly result). ROE was negative in the same quarter of the previous year due to the recognition of a loss, indicating that profitability is in a recovery phase.【Financial Soundness】The Equity Ratio increased to 31.2% from 29.8% in the previous year, an increase of +1.4pt. However, Current Assets of ¥175.22B versus Current Liabilities of ¥187.47B resulted in a relatively low Current Ratio of 0.94x. Goodwill was ¥223.37B, representing 41.1% of Total Assets and 132.6% of Net Assets.

Cash Flow Analysis

Operating Cash Flow was ¥14.33B, up 166.2% from ¥5.38B in the previous year. In addition to the sharp recovery in Profit Before Tax, a ¥4.50B decrease in trade receivables supported cash generation, while a ¥4.82B decrease in trade payables and a ¥1.47B increase in inventories partially offset cash generation. Investing Cash Flow was ¥-3.31B, including capital expenditures of ¥2.73B, which remained below depreciation and amortization of ¥6.69B, indicating a restrained investment stance. Financing Cash Flow was ¥-10.02B, with the main outflows consisting of dividend payments of ¥2.49B, repayments of long-term borrowings of ¥5.96B, and lease payments of ¥1.59B. Free Cash Flow was ¥11.02B, exceeding dividend payments and capital expenditures, and Cash and Cash Equivalents increased to ¥41.28B.

Quality of Earnings

The earnings growth for the quarter was driven by recurring factors—expansion in Operating Income and a decline in finance costs. The impact of Other Income of ¥0.81B (0.9% of Revenue) and impairment reversals of ¥0.03B was limited, suggesting a low degree of dependence on nonrecurring factors. Operating Cash Flow of ¥14.33B, equivalent to 2.3 times consolidated Net Income of ¥6.29B, indicates favorable earnings quality from an accrual perspective. Total Comprehensive Income of ¥10.12B (including ¥10.18B attributable to owners of the parent) exceeded Net Income attributable to owners of the parent of ¥6.34B by ¥3.84B. This difference resulted from foreign currency translation adjustments of ¥3.35B for foreign operations and remeasurements of defined benefit plans of ¥0.92B recognized in Other Comprehensive Income, representing foreign exchange and pension-related factors distinct from operating results.

Earnings Forecast and Guidance

The Q1 progress rates against the Full-Year forecast—Revenue of ¥35.97B, Operating Income of ¥2.70B, and Net Income attributable to owners of the parent of ¥1.54B—were 25.2%, 38.6%, and 41.2%, respectively. Progress in both Operating Income and Net Income significantly exceeded the simple quarterly allocation of 25%, supported by higher margins in Diabetes Management and improved SG&A efficiency. No revisions were made to the earnings forecast or dividend forecast as of the quarter under review.

Shareholder Returns

The Full-Year dividend forecast is ¥42.00 per share, representing a Payout Ratio of 34.5% based on forecast EPS of ¥121.73. Dividend payments during Q1 amounted to ¥2.49B and were sufficiently covered by Free Cash Flow of ¥11.02B. No share repurchases were made during Q1, and shareholder returns remain centered on dividends.

Risk Factors

1. Goodwill impairment risk: Goodwill was ¥223.37B, representing 41.1% of Total Assets and 132.6% of Net Assets. If the business plan falls short, the scale of goodwill could result in a relatively significant impact on Equity through the recognition of impairment losses.

2. Liquidity and financial structure: The Current Ratio was 0.94x, below 1x, while Cash and Cash Equivalents of ¥41.28B remained below Short-Term Borrowings of ¥78.29B. Although the Equity Ratio of 31.2% has improved from the previous year, continued monitoring of the debt structure remains important.

3. Concentration of segment earnings: Diabetes Management accounted for 75.9% of total segment Operating Income of ¥12.09B. The profitability of Healthcare Solutions (3.5% margin) and Diagnostics & Life Sciences (5.7% margin) was relatively low. The company remains highly dependent on a specific segment for earnings.

Industry Benchmark (Reference; Company Analysis)

Industry Benchmark (manufacturing)

Profitability and Returns

The Operating Margin exceeds the industry median, while the Net Profit Margin remains approximately in line with the median, indicating a difference in the company's relative positioning at the operating and net profit levels.

Growth and Capital Efficiency

The Revenue Growth Rate exceeds the industry median and is positioned toward the upper end of the IQR.

※Source: Company compilation

Key Takeaways from the Earnings Results

1. The Operating Margin expanded from 4.6% in the previous year to 11.5%, an increase of +690bp, supported by both an improvement in the Gross Margin (+200bp) and a decline in the SG&A Expense Ratio (-420bp). Growth in the Diabetes Management Business (+20.2%) and its higher margin (33.0%) represent a turning point in the company's overall earnings structure.

2. Operating Cash Flow was ¥14.33B, equivalent to 2.3 times consolidated Net Income, providing solid cash backing for earnings. Free Cash Flow of ¥11.02B exceeded dividend payments and capital expenditures, while the Equity Ratio also improved to 31.2%.

3. Progress against the Full-Year plan was 38.6% for Operating Income and 41.2% for Net Income attributable to owners of the parent, significantly exceeding the simple allocation of 25% and indicating front-loaded earnings progress in the first half.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a Residual Income Model (Ohlson-type model with an explicit 5-year fade period). It is not a forecast of the market share price or a recommendation to take any specific investment action.

Sensitivity: ¥1,305–¥1,382 at Cost of Equity ±1%, and ¥1,342–¥1,343 at ω±0.1.

Notes:

• Because Net Income progress against the Full-Year forecast (41%) exceeds the standard level (25%), forecast EPS has been adjusted upward within an upper limit of +10% (because companies with front-loaded progress tend to outperform their forecasts; however, the adjustment may be excessive for businesses with strong seasonality).
• Goodwill represents a high proportion of Net Assets, and the assumptions would change significantly if impairment were recognized.
• Net Assets at the end of the quarter are used, resulting in a timing difference from the Full-Year forecast.

(Calculation model: Residual Income Model / Interest rate reference month: 2026-07 / This figure is not intended to forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with professionals as necessary.

---End of Report---